Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mycomagic Biotechnology Co. Ltd. currently manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company is navigating 2 pending office actions. These actions are distributed across 2 distinct examiners, indicating that each examiner is currently reviewing a separate application. Furthermore, the prosecution is occurring within 2 distinct art units, which suggests a breadth of technical classification even within the company's primary technology sector.
RICCI, CRAIG D is identified as the busiest examiner for this portfolio. This examiner is currently responsible for 1 busiest examiner pending action. Because the total number of pending actions is 2 and there are 2 distinct examiners, the workload is evenly distributed. Practitioners should note that the presence of 2 distinct art units for 2 actions means that the company's current filings are not concentrated in a single specialized group at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.5% | +52.7% |
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18792473 | EXOSOME COMPOSITION CONTAINING GANODERMA IMMUNOMODULATORY PROTEIN AND USES THEREOF | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18792473 | EXOSOME COMPOSITION CONTAINING GANODERMA IMMUNOMODULATORY PROTEIN AND USES THEREOF | RICCI, CRAIG D | 1611 | §103 | Final Rejection | — | Pending | Aug 01, 2024 |
| 17821291 | IMMUNOMODULATORY PROTEIN FOR PREVENTION OF CORONAVIRUS INFECTION | SPAINE, ROBERT FRANKLIN | 1600 | §112Other | Non-Final OA | — | Pending | Aug 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial